Q1 Earnings Forecast for ZNTL Issued By Leerink Partnrs

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.68) per share for the quarter. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.42) EPS.

A number of other analysts have also weighed in on ZNTL. Guggenheim dropped their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company cut their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Finally, HC Wainwright dropped their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Up 0.9 %

Shares of ZNTL opened at $2.16 on Friday. The stock has a 50 day simple moving average of $2.81 and a two-hundred day simple moving average of $3.21. Zentalis Pharmaceuticals has a 1 year low of $1.61 and a 1 year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Jan Skvarka acquired 60,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares in the company, valued at $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at $68,000. Charles Schwab Investment Management Inc. raised its position in Zentalis Pharmaceuticals by 22.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock valued at $1,507,000 after purchasing an additional 91,152 shares in the last quarter. Anfield Capital Management LLC raised its position in Zentalis Pharmaceuticals by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock valued at $392,000 after purchasing an additional 64,659 shares in the last quarter. Ieq Capital LLC bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $46,000. Finally, Savant Capital LLC bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $72,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.